Abstract:e22094 Background: The immune therapy of human cancer is a promising therapeutic approach. Myeloid-derived suppressor cells (MDSCs) have been confirmed as an indispensable component of immune system and associated with tumor induced immune suppression. Thus, MDSCs play an important role in immune therapy. Although a lot of research work has been done, currently there exists limited data about MDSCs status in cancer patients. The aim of this study was to determine whether MDSCs levels in peripheral blood were different in healthy volunteers, benign breast tumor patients and breast cancer patients, and to investigate the relation between MDSCs and several characteristics in breast cancer patients. Methods: Peripheral blood cells (PBC) were collected from 36 normal healthy volunteers, 52 patients with breast cancer and 62 patients with benign breast tumor. Peripheral blood samples of breast cancer patients were obtained before treatment. Circulating MDSCs (identified as Lin-/Lo HLA-DR-CD33+) were measured by flow cytometry. Statistical methods included two sample t tests and one way ANOVA. Results: The percentage of MDSCs was higher in breast cancer than benign breast tumor patients and healthy volunteers (2.017% vs 1.578% vs1.594%; p=0.0002), and the stage III/IV breast cancer patients had more MDSCs accumulation than those in stage I/II (2.92% vs 2.155%; P=0.0806). The levels of MDSCs in peripheral blood showed a significant correlation with HER-2/neu expression in breast cancer patients, but had no correlation with incidence age, ER status, PR status and P53 expression respectively. The percentage of MDSCs was lower in HER-2/neu over expression breast cancer patients than HER-2/neu negative patients (1.715% vs 2.882%, GP=0.0012). Conclusions: MDSCs seemed to have positive correlation with clinical stage and negative correlation with HER-2/neu expression in breast cancer patients . Further research will contribute to the better understanding of the connection between MDSCs and breast cancer, to develop better approaches to breast cancer therapy.

Peripheral blood monocyte M2/M1 ratio for the diagnosis of breast cancer

Prognostic Significance of Pre-Operative Monocyte-to-Lymphocyte Ratio in Lung Cancer Patients Undergoing Radical Surgery

Combined determination of plasma hyaluronan and the ratio of M2 monocyte/M1 monocyte ratio in breast cancer

Increased circulating M2-like monocytes in patients with breast cancer.

Combination of Plasma HA and Circulating M2-like Monocytes May Serve As a Diagnostic Marker for Breast Cancer

Association of Myeloid-Derived Suppressor Cells (mdscs) in Peripheral Blood with Characteristics in Breast Cancer Patients.

Value of Peripheral Blood MUC1 Mrna and Cyfra21-ⅰ in Diagnosis of Non-Small Cell Lung Carcinoma

Increased Percentage of Mo-Mdscs in Human Peripheral Blood May Be a Potential Indicator in the Diagnosis of Breast Cancer.

CD16+ Monocytes in Breast Cancer Patients: Expanded by Monocyte Chemoattractant Protein-1 and May Be Useful for Early Diagnosis.

[Detection and Clinical Significance of Circulating Tumor Cells in Peripheral Blood of Breast Cancer Patients].

Prognostic Evaluation of Metastasis-Related Lymphocyte/Monocyte Ratio in Stage Ⅰ-Ⅲ Breast Cancer Receiving Chemotherapy

Investigation on the Correlation Between Circulating Tumor Cells and Cancer Stem Cells in Patients with Breast Cancer

Cancer Antigen 15-3, Platelet Distribution Width, and Fibrinogen in Combination to Distinguish Breast Cancer from Benign Breast Disease in Non-Conclusive Mammography Patients

The sensitivity and specificity of G2 serum SDF-1 combined with CXCL5 and CEA in the diagnosis of breast cancer

The Clinical Application Value of RDW, CA153, and MPV in Breast Cancer.

Circulating tumor cells in peripheral blood as a diagnostic biomarker of breast cancer: A meta-analysis

Research on the Relationship of Mrna Expressions CEA,Survivin,MMP-2 and TIMP-2 in Peripheral Blood with Breast Carcinoma

Prognostic significance of preoperative circulating monocyte count in patients with breast cancer based on a large cohort study

Association of circulating Progesterone Receptor Membrane Component-1 (PGRMC1) with breast tumor characteristics and comparison with known tumor markers

Detection of SBEM-mRNA level in peripheral blood of patients with breast cancer and its clinical significance

Correlation between Pretreatment Hematologic Parameters and Cervical Cancer Patients Undergoing Hysterectomy: a Retrospective Study